{
  "schema_version": "1.3.1",
  "doc": {
    "doc_id": "7786ab111f0ee8a06ae64a3e74849a47",
    "title": "Jefferies",
    "source_uri": "2025-08-31/Roger That Weekly Updates and Discussions BMEA UTHR ALT PTGX GPCR TRMLRoger That Weekly Updates and Discussions BMEA UTH_2025-08-31",
    "language": "en",
    "timestamps": {
      "ingested_at": "2025-10-27T00:44:40.570044",
      "extracted_at": "2025-10-27T00:44:40.570051"
    },
    "extraction_run": {
      "vision_model": "deepseek-ai/DeepSeek-OCR",
      "synthesis_model": "rule-based-engine",
      "pipeline_steps": [
        "ocr",
        "rule_extraction",
        "figure_vision"
      ],
      "processing_metadata": {
        "pages_processed": 13,
        "successful_pages": 13,
        "date": "2025-08-31",
        "publication": "2025-08-31",
        "authors": [],
        "markdown_cleaning": {
          "removed_sections": 2,
          "removed_paragraphs": 10,
          "reduction_ratio": 0.1781204803614086
        },
        "input_relative_path": "2025-08-31"
      }
    }
  },
  "passages": [
    {
      "passage_id": "23fe0f0d6028793e",
      "text": "Roger That: Weekly Updates and Discussions - BMEA, UTHR, ALT, PTEX, GPCR, TRML",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "f5556fa64558e30a",
      "text": "We highlight forward- looking updates/tidbits on our coverage/key comps/adjacencies and takes from investor/company discussions. BMEA: initiate at Buy, PT \\(\\) 5\\(. UTHR: expands MNKD collab for QD DPI (NME) dev't. ALT: CDER considers non- invasive EP in MASH approval. PTEX: rufsteride granted BTD for erythrocytosis in PV. GPCR: comp ofo Ph3 T2D/obesity data no surprise, leaving room for differentiations. TRML: new publication on causal relation between IL6 and ASCVD.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "9f1b09dafa0b6be6",
      "text": "BMEA (8/28): \\*Slides\\* Menin for \\~7M+ Insulin- deficient Diabetes - Initiate at Buy, PT \\(\\) 5\\$",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "fe43035aa179ac7b",
      "text": "- (8/24) Relevant to Our HemOnc / I&I / Endo/ Other Coverage- (8/24) Relevant to Our Cardiometabolic/ Genetics/ Vaccine Coverage",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "3d65d285e81d9a06",
      "text": "Weekly Tracker: Obesity (8/23), Vaccine (8/23)",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "1242f775967609fa",
      "text": "UTHR: Co expands MannKind collab to accelerate QD dry powder inhalation for pulmonary hypertension. The original agreement which led to Tyvaso DPI approval in May '22 incl. an option for UTHR to expand the license to incl addit active ingredients. Under the expanded agreement, MNKD will formulate a 2nd investigational molecule using its proprietary Technosphere platform, and UTHR will conduct preclinical/ clinical development. MNKD will receive \\(\\) 5\\$ M upfront and is eligible for up to \\(\\) 35\\$ M development milestones + 10% royalties on net sales of any resulting product. Formulation/ development activities will begin immediately.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "0b5da341410c9fd6",
      "text": "ALT: FDA's CDER accepted a letter of intent proposal to use a non- invasive surrogate endpoint in MASH clinical trial approvals. This decision could allow liver stiffness assessed using Vibration- Controlled Transient Elastography as a surrogate EP in evaluating new MASH Tx w/o requiring repeat liver biopsies. The proposal laid out biomarker's ability to predict risk of all- cause mortality or liver- related events in MASH pts, correlating w/ liver fibrosis severity. Liver biopsies are logistically challenging and pose safety risks due to its invasive nature. This decision could speed up trial recruitment, increase representation in pt pop, and accelerate development.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "ecd100a2070e29a8",
      "text": "PTGX: Ruserfide receives BTD for treatment of erythrocytosis in pts w/ Polycythemia Vera. The BTD was supported by the 32W data from Ph3 VERIFY Study. BTD conveys eligibility for priority NDA review. Co remains on track for NDA submission in PV by YE25. Ruserfide also has ODD that qualifies sponsors for various incentives incl a potential for extended market exclusivity.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "07f409563b750125",
      "text": "GPCR: Comp orfo Ph3 ATTAIN- 2 (+ ) topline obesity/ overweight and T2D and plans for global regulatory submissions by YE25. Orfo met weight loss (WL) 1EP, as well as all key 2EPs for all 3 doses tested. At the highest dose 36mg, pts got 10.5% WL vs 2.2% pbo and a decreased in HbA1c of 1.8% vs 0.1% pbo. WL was unsurprisingly lower than ATTAIN- 1 (non- T2D obesity). GI AE/ tolerability was comparable to ATTAIN- 1, and oral/ inj sema, importantly without liver tox. Overall, we continue",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "d57802b1e6cdf2ec",
      "text": "to see positive readthrough to GPCR given efficacy leaving room to differentiate and AE profile validating dosing strategy.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "a07044c41243017e",
      "text": "TRML: Co publishes new findings that highlight causal association b/w IL- 6 pathway and ASCVD to provide further support for development of pacibektug (IL- 6 inhibitor) for ASCVD. Findings from a large human genetic study (published in Nature Cardiovascular Research) found a consistently lower risk of ASCVD in people with genetically proxied IL- 6 cytokine inhibition. This paper also outlines potential benefits in targeting IL- 6 cytokine vs IL- 6 receptor, incl larger reductions in the risk of peripheral artery disease and ischemic stroke and lower risk of severe infections.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "bbee6915f511fa2a",
      "text": "CategoryCompanyTibitsVaccinesINOFDA agrees w/INO-3107 rolling submission timelineMetabolicsNVO/Replicate Biosciencepartnership on self-replicating RNA for obesity and diabetesOthersNA1st lung xenotransplant attempt conducted on brain-dead person",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "1506745969a62c43",
      "text": "Source: Company reports",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "b4e10b7efca761ed",
      "text": "See the full report for much more detail on the above highlights and \"tidbits.\"",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "f767c8ac9da127e1",
      "text": "Chart 1 - Key 2H25 Stock-moving Catalysts (Highlights for Major Events in The Upcoming Three Months)",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "6c3aee399c466365",
      "text": "Company ProgramIndicationTimeUnitImpactACRVACR-368Endometrial cancerYE25agestrational path updateACRVACR-2316Solid tumorsYE25AKBAVafseoDD-CKD/ anemia2025Quarterly salesALTPemvidutideMASH4025Ph2b 48W biopsy dataALTPemvidutideMASH4023ECP2 meeting feedbackATYREfiofitimedPulmonary sarcoidosisM4-5pt 25Ph3topline dataBIOAIGE-102 (NLP9 3)ObesityYE25Ph1 SA0 dataBMEAIcovamenibT2DSept/Oct 25Ph2 52W data for T2D and T1DCLDXBarzolvlimabCindU2025Ph2 44W dataCRVSSonoVitinib (CP-818)Atopic dermatitis4025Ph1b expansion dataCTMXCK-801Melanoma2025Ph1a initial monots biomarker dataCVACN/AN/A2025BNTX acquisition del completionGPCRACCG-2671Obesity20252nd small molecule amylin D/CGPCRGSBR-1290Obesity2025Ph2b 36W topline dataGPCRGSBR-1290Obesity and T2D3025-4025Initiate 3 Ph2 in maintenance switch/body composition/T2DINOINO-3107RRP vaccineYE25BLA acceptanceOBTO102-01031L advanced melanoma2025FDA Pre-BLA meeting feedbackIOBTO102-01031L advanced SCCHN2025Ph2 mature DOR dataIONDSC-0974Myelofibrosis/ anemia4025 (ASH)Ph2 initial dataIRONDSC-0974CKD/ anemia2025Ph1b MAD dataIRONBitopertinEPPOct25NDA submissionKNSAAcralystRecurrent pericarditis25Quarterly salesKRVSKB407Cystic fibrosisYE25Ph1 cohort 3 dataKURAZfitomenibr/r AML with NPM2mNov 30thPDUFA dateKURAZfitomenib1L AML with NPM2m/KMT2ar2025Ph3 KOMET-017 Combo w/ \"7+3\" or \"Ven/aa\" initiationKURAZfitomenib1L AML with targeted Mutations25 (ASH)KOMET-007 Ph1b ziftov ven/aa combo detailed dataMBXMBX-2109hypoparathyroidism3025Topline data from Ph2 12W studyNKTRRespegAlopecia areata4025Ph2b topline dataNRXBexobrutide (NK-5948)CLL, NHL2025Ph1a/b data updateNRXBexobrutide (NK-5948)CLL, NHL20253L+ C1l pivotal initiation and regulatory updateNRXZelebrodimide (NK-2127)NHL2025Ph1a data updateNRXNX-1607 (CBL-B)Solid tumorESMO25Ph1a data updateNUVLZidesamtinib (NVL-520)ROS1+ NSCLCWCLC25Ph2 detailed pivotal data + preliminary data from TKI-naiveNUVLNelalekib (NVL-655)ALK+NSCLC (pretreated)by YE25Ph2 initial pivotal dataNUVLNelalekib (NVL-655)ALK+ solid tumors (beyond NSCLC)ESMO25Preliminary dataNVAXNVX-Cv2373CV19 vaccine202525/26 season sales (via partner Sanofi)PCVXVAX-31Pneumococcal vaccine4025Ph3 adult startPCVXVAX-24Pneumococcal vaccine2025Ph2 booster data in infantsPRLDPRT3789 (IV)SMARCA4d cancersYE25Ph1 final monots and docetaxel combo dataPRLDPRT7732 (oral degrader)SMARCA4d cancersYE25Ph1 interim dataPTGXIcotrokinra (JNJ-2113)Ulcerative colitisUEGW25 (10/7/25)Ph2b detailed dataPTGXIcotrokinra (JNJ-2113)Psoriasis2025Ph3 CONC-ADVANCE (TYC2 H2h) dataREPLRP1aPD1 refractory melanoma2025FDA Type A meeting and feedbackSANAUP-021T1D2025Long-term follow-up dataTGTXBritumviMultiple sclerosis2025Quarterly earningsTRMLPaclibextin (TOUR006)ASCVD2025ECP2 meetingUTHRTyvasoPAH/ PH-ILD2025Quarterly earningsUTHRTyvasoIPFSept 25Ph3 TETON2 (global) dataVKXTVK2735 (oral)ObesitySept/Oct 25Ph2a 13W detailed/ follow-up dataVKXTNorovirusNorovirus vaccine2025Potential partnershipWHWKHWX-007 (PTK7)Solid tumor2025IND fillingWHWKMUC16Gynecologic cancerYE25IND fillingWHWKCPT113 (partner)Solid tumor (CD56, TROP2)Likely 25Initial Ph1 dataWVEWVE-006AATD302/4f1 25Ph1 200mg MAD and 400mg SAD data updateWVEWVE-003Huntington's disease2025IND filling for potential registration Ph2/3 trialWVEWVE-007Obesity2025Ph1 first 2 cohorts data updateZIBOObezelimabMultiple sclerosisEarly 4025Ph2 topline dataZIBOObezelimabIgG4-RD2025Ph2 topline data",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "46a8ab2939c4122a",
      "text": "Source: Company reports and Jefferies research",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "bf0c568f3a03915b",
      "text": "Significant (>50% stock movement), high (30-50%), medium (10-30%), modest (",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "c5db389967114171",
      "text": "Significant (>50% stock movement), high (30-50%), medium (10-30%), modest (",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "32014cd06209e1e5",
      "text": "INO: Co will begin rolling submission of INO- 3107 for treatment of RRP in adults. Co announced that FDA has notified Co that it agrees with its rolling submission timeline for the BLA of INO- 3107 as a treatment for adults with Recurrent Respiratory Papillomatosis (RRP). Co anticipates completing submission in the coming months and requesting priority review, with the goal of file acceptance by YE25.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "3ccfb9418184cf03",
      "text": "NVO: Co partners with Replicate Bioscience to develop self- replicating RNA therapies for obesity and diabetes. Under the terms of the partnership, Replicate is eligible to receive up to US \\(500M in exchange for an exclusive worldwide license to use its self- replicating RNA platform to develop and commercialize lead programs for cardiometabolic diseases. The agreement includes an up- front cash payment, potential milestone payments, and potential tiered royalties on future product sales. Replicate's currently most advanced assets target IL- 1RA and IL- 1B binding protein to block inflammasome activation which plays a role in diseases such as chronic IBD, gout, and recurrent pericarditis.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "6f84e7001344c921",
      "text": "Xenotransplant: 1st lung xenotransplant conducted on a brain- dead person. Researchers in China took the lung from a CRISPR edited pig (Bama miniature pig, Clonorgan Biotechnology, Chengdu, China) and transplanted to a 39- year old brain- dead person. No hyperacute rejection was seen in the 1st 24h. However, increased pro- inflammatory molecules and white blood cells began infiltrating the pig lung by 24h, along with fluid build up in the new organ. By day 3, signs of antibody- mediated rejection of the lung was noted. On day 9, the experiment was terminated at the request of the recipient's family. Note, one limitation of the study was that by leaving behind the right lung of the patient, the group was not able to assess whether the pig lung was life- supporting. The team is planning to perform more transplants into brain- dead patients, and those future experiments will explore testing bilateral lung transplantation, evaluating pig lungs with more gene edits, and refining the immunosuppressive regimen. Lung xenotransplantation presents unique biological and technical challenges compared to other organs, as lung is continually exposed to the outside air, including any bacteria, viruses, pollen, or environmental toxins, while the biological structures that facilitate the gas exchange make the organ very fragile compared to the muscular heart or the stem- cell laden liver, which can regenerate after damage. The procedure marks the 1st attempt for xenotransplant of lung.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "7576fcdd567e8ec0",
      "text": "For Important Disclosure information on companies recommended in this report, please visit our website at https://javatar.bluematrix.com/sellside/Disclosures.action or call 212.284.2300.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "14951055e2cce47b",
      "text": "(Article 3(1)e and Article 7 of MAR) Recommendation Published Recommendation Distributed",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "a35d7e1ab549f64d",
      "text": "August 29, 2025 16:45 P.M. August 31, 2025 11:00 A.M.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "a73617fde5b82ee3",
      "text": "Jefferies Financial Group Inc., its affiliates or subsidiaries make a market in the securities or ADRs of BioAge Labs Inc. Jefferies Financial Group Inc., its affiliates or subsidiaries make a market in the securities or ADRs of Celldex Therapeutics, Inc. Jefferies Financial Group Inc., its affiliates or subsidiaries make a market in the securities or ARDs of Disc Medicine Inc. Jefferies Financial Group Inc., its affiliates or subsidiaries make a market in the securities or ADRs of Prelude Therapeutics, Inc. Jefferies Financial Group Inc., its affiliates or subsidiaries make a market in the securities or ARDs of TG Therapeutics, Inc. Jefferies Financial Group Inc., its affiliates or subsidiaries make a market in the Securities or ADRs of Tourmaline Bio, Inc.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "e5119ced180f4417",
      "text": "Jefferies Financial Group Inc., its affiliates or subsidiaries expect to receive or intend to seek compensation for investment banking services from ATYR PHARMA, INC. within the next three months.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "9bd3cb9f458160ea",
      "text": "Within the past 12 months, Jefferies Financial Group Inc., its affiliates or subsidiaries has received compensation from investment banking services from ATYR PHARMA, INC.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "4f356f6626bea4dd",
      "text": "Jefferies Financial Group Inc., its affiliates or subsidiaries is acting as a manager or co- manager in the underwriting or placement of securities for ATYR PHARMA, INC. or one of its affiliates.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "27fcb6f4862a05a3",
      "text": "Jefferies Financial Group Inc., its affiliates or subsidiaries has acted as a manager or co- manager in the underwriting or placement of securities for ATYR PHARMA, INC. or one of its affiliates within the past twelve months.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "1bae3cbc614554be",
      "text": "Within the past twelve months, ATYR PHARMA, INC. has been a client of Jefferies Financial Group Inc., its affiliates or subsidiaries and investment banking services are being or have been provided.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "7dfa15689f7704b6",
      "text": "Within the past 12 months, Jefferies Financial Group Inc., its affiliates or subsidiaries has received compensation from investment banking services from BioAge Labs Inc.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "4365f8bdaa338569",
      "text": "Jefferies Financial Group Inc., its affiliates or subsidiaries has acted as a manager or co- manager in the underwriting or placement of securities for BioAge Labs Inc or one of its affiliates within the past twelve months.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "dbc16b2c05f5c523",
      "text": "Within the past twelve months, BioAge Labs Inc has been a client of Jefferies Financial Group Inc., its affiliates or subsidiaries and investment banking services are being or have been provided.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "c8ca3fadebda9bd1",
      "text": "Jefferies Financial Group Inc., its affiliates or subsidiaries beneficially owned \\(1\\%\\) or more of the common equity of BioAge Labs Inc as of last month's end (or the prior month's end if this report is dated later than 10 days after the most recent month end).",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "80c0b66aeffd7ec5",
      "text": "Jefferies Financial Group Inc., its affiliates or subsidiaries expect to receive or intend to seek compensation for investment banking services from Biomea Fusion within the next three months.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "ca36bb6ff013d4bc",
      "text": "Within the past 12 months, Jefferies Financial Group Inc., its affiliates or subsidiaries has received compensation from investment banking services from Biomea Fusion.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "d6c58690b838e296",
      "text": "Jefferies Financial Group Inc., its affiliates or subsidiaries has acted as a manager or co- manager in the underwriting or placement of securities for Biomea Fusion or one of its affiliates within the past twelve months.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "e10be62d55caa47d",
      "text": "Within the past twelve months, Biomea Fusion has been a client of Jefferies Financial Group Inc., its affiliates or subsidiaries and investment banking services are being or have been provided.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "15337ead6546f0a5",
      "text": "Jefferies Financial Group Inc., its affiliates or subsidiaries expect to receive or intend to seek compensation for investment banking services from Corvus Pharmaceuticals, Inc. within the next three months.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "69d919187b7056fa",
      "text": "Within the past 12 months, Jefferies Financial Group Inc., its affiliates or subsidiaries has received compensation from investment banking services from Corvus Pharmaceuticals, Inc.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "976c4504ac783659",
      "text": "Jefferies Financial Group Inc., its affiliates or subsidiaries is acting as a manager or co- manager in the underwriting or placement of securities for Corvus Pharmaceuticals, Inc. or one of its affiliates.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "56960de1f2c10966",
      "text": "Jefferies Financial Group Inc., its affiliates or subsidiaries has acted as a manager or co- manager in the underwriting or placement of securities for Corvus Pharmaceuticals, Inc. or one of its affiliates within the past twelve months.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "b3505dac0e27fa30",
      "text": "Within the past twelve months, Corvus Pharmaceuticals, Inc. has been a client of Jefferies Financial Group Inc., its affiliates or subsidiaries and investment banking services are being or have been provided.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "0f10d7c10f7494b7",
      "text": "Jefferies Financial Group Inc., its affiliates or subsidiaries expect to receive or intend to seek compensation for investment banking services from CytomX Therapeutics, Inc. within the next three months.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "0944e32152557d70",
      "text": "Within the past 12 months, Jefferies Financial Group Inc., its affiliates or subsidiaries has received compensation from investment banking services from CytomX Therapeutics, Inc.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "7a88a08c9ddf2f68",
      "text": "Jefferies Financial Group Inc., its affiliates or subsidiaries is acting as a manager or co- manager in the underwriting or placement of securities for CytomX Therapeutics, Inc. or one of its affiliates.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "5511554bffbfa764",
      "text": "Jefferies Financial Group Inc., its affiliates or subsidiaries has acted as a manager or co- manager in the underwriting or placement of securities for CytomX Therapeutics, Inc. or one of its affiliates within the past twelve months.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "c18133d0279fe61a",
      "text": "Within the past twelve months, CytomX Therapeutics, Inc. has been a client of Jefferies Financial Group Inc., its affiliates or subsidiaries and investment banking services are being or have been provided.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "6e7271ae5af55459",
      "text": "Jefferies Financial Group Inc., its affiliates or subsidiaries expect to receive or intend to seek compensation for investment banking services from CureVac N.V. within the next three months.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "49b3b8d542c93095",
      "text": "Within the past 12 months, Jefferies Financial Group Inc., its affiliates or subsidiaries has received compensation from investment banking services from CureVac N.V.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "e7c11da477f5e6f1",
      "text": "Within the past twelve months, Jefferies Financial Group Inc. and/or its affiliates received compensation for products and services other than investment banking services from non- investment banking, securities related compensation for client services it provided to CureVac N.V.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "56506656c0e6807d",
      "text": "Jefferies Financial Group Inc., its affiliates or subsidiaries is acting as a manager or co- manager in the underwriting or placement of securities for CureVac N.V. or one of its affiliates.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "09e8bbe5b0ffade8",
      "text": "Jefferies Financial Group Inc., its affiliates or subsidiaries has acted as a manager or co- manager in the underwriting or placement of securities for CureVac N.V. or one of its affiliates within the past twelve months.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "1c590e83ccfe16ee",
      "text": "Within the past twelve months, CureVac N.V. has been a client of Jefferies Financial Group Inc., its affiliates or subsidiaries and investment banking services are being or have been provided.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "9c9cf928c3884725",
      "text": "Jefferies International Ltd, its affiliates or subsidiaries has, or had, within the past 12 months an agreement to provide investment services to Disc Medicine Inc. Jefferies Financial Group Inc., its affiliates or subsidiaries is acting as a manager or co- manager in the underwriting or placement of securities for Disc Medicine Inc or one of its affiliates.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "75de86f42c8802a8",
      "text": "Within the past 12 months, Jefferies Financial Group Inc., its affiliates or subsidiaries has received compensation from investment banking services from Disc Medicine Inc.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "7f8fc64b8f487cfc",
      "text": "Within the past twelve months, Jefferies Financial Group Inc. and/or its affiliates received compensation for products and services other than investment banking services from non- investment banking, securities related compensation for client services it provided to Disc Medicine Inc.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "8e31f609b2382040",
      "text": "Within the past twelve months, Disc Medicine Inc has been a client of Jefferies Financial Group Inc., its affiliates or subsidiaries and investment banking services are being or have been provided.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "a164e4b88376e404",
      "text": "Jefferies Financial Group Inc., its affiliates or subsidiaries has acted as a manager or co- manager in the underwriting or placement of securities for Disc Medicine Inc or one of its affiliates within the past twelve months.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "2ac087c9683a0a80",
      "text": "Within the past 12 months, Jefferies Financial Group Inc., its affiliates or subsidiaries has received compensation from investment banking services from MBX Biosciences, Inc.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "eda243a8d6e8e929",
      "text": "Jefferies Financial Group Inc., its affiliates or subsidiaries has acted as a manager or co- manager in the underwriting or placement of securities for MBX Biosciences, Inc. or one of its affiliates within the past twelve months.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "7ce8ac82012e7f7d",
      "text": "Within the past twelve months, MBX Biosciences, Inc. has been a client of Jefferies Financial Group Inc., its affiliates or subsidiaries and investment banking services are being or have been provided.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "0f9c6dc8a7c244d1",
      "text": "Jefferies Financial Group Inc., its affiliates or subsidiaries expect to receive or intend to seek compensation for investment banking services from Nektar Therapeutics within the next three months.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "1640bd17475d33ca",
      "text": "Within the past 12 months, Jefferies Financial Group Inc., its affiliates or subsidiaries has received compensation from investment banking services from Nektar Therapeutics.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "a83567ca2e0dc950",
      "text": "Jefferies Financial Group Inc., its affiliates or subsidiaries has acted as a manager or co- manager in the underwriting or placement of securities for Nektar Therapeutics or one of its affiliates within the past twelve months.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "9ea4c0839f6a0640",
      "text": "Within the past twelve months, Nektar Therapeutics has been a client of Jefferies Financial Group Inc., its affiliates or subsidiaries and investment banking services are being or have been provided.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "4aeae7fd24ce4ca1",
      "text": "Within the past 12 months, Jefferies Financial Group Inc., its affiliates or subsidiaries has received compensation from investment banking services from Nuvalent Inc.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "0f7bdff7e17088c5",
      "text": "Jefferies Financial Group Inc., its affiliates or subsidiaries has acted as a manager or co- manager in the underwriting or placement of securities for Nuvalent Inc or one of its affiliates within the past twelve months.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "7df6f4ee553f6fa9",
      "text": "Within the past twelve months, Nuvalent Inc has been a client of Jefferies Financial Group Inc., its affiliates or subsidiaries and investment banking services are being or have been provided.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "edcc43760aff465e",
      "text": "Jefferies Financial Group Inc., its affiliates or subsidiaries expect to receive or intend to seek compensation for investment banking services from Novavax, Inc. within the next three months.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "6dc6058eedc7cb2d",
      "text": "Jefferies Financial Group Inc., its affiliates or subsidiaries is acting as a manager or co- manager in the underwriting or placement of securities for Novavax, Inc. or one of its affiliates.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "bf7ad3d762f515da",
      "text": "Within the past 12 months, Jefferies Financial Group Inc., its affiliates or subsidiaries has received compensation from investment banking services from Novavax, Inc.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "ef38dd5c7470c8c5",
      "text": "Within the past twelve months, Novavax, Inc. has been a client of Jefferies Financial Group Inc., its affiliates or subsidiaries and investment banking services are being or have been provided.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "3c225872d30d75b1",
      "text": "Jefferies Financial Group Inc., its affiliates or subsidiaries has acted as a manager or co- manager in the underwriting or placement of securities for Novavax, Inc. or one of its affiliates within the past twelve months.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "02890c49281b3994",
      "text": "Jefferies Financial Group Inc., its affiliates or subsidiaries expect to receive or intend to seek compensation for investment banking services from Vaxcyte, Inc. within the next three months.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "4ad4de5d3d676750",
      "text": "Within the past 12 months, Jefferies Financial Group Inc., its affiliates or subsidiaries has received compensation from investment banking services from Vaxcyte, Inc.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "dc8d054220bf11da",
      "text": "Jefferies Financial Group Inc., its affiliates or subsidiaries is acting as a manager or co- manager in the underwriting or placement of securities for Vaxcyte, Inc. or one of its affiliates.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "c4b4f43ccd57b85c",
      "text": "Jefferies Financial Group Inc., its affiliates or subsidiaries has acted as a manager or co- manager in the underwriting or placement of securities for Vaxcyte, Inc. or one of its affiliates within the past twelve months.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "0f7c5e672a11ebc0",
      "text": "Within the past twelve months, Vaxcyte, Inc. has been a client of Jefferies Financial Group Inc., its affiliates or subsidiaries and investment banking services are being or have been provided.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "09d77d88740b4619",
      "text": "Jefferies International Ltd, its affiliates or subsidiaries has, or had, within the past 12 months an agreement to provide investment services to Vaxcyte, Inc. Within the past 12 months, Jefferies Financial Group Inc., its affiliates or subsidiaries has received compensation from investment banking services from Prelude Therapeutics, Inc.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "4ca59eae04e165ef",
      "text": "Jefferies Financial Group Inc., its affiliates or subsidiaries has acted as a manager or co- manager in the underwriting or placement of securities for Prelude Therapeutics, Inc. or one of its affiliates within the past twelve months.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "b4eb9ede76dbee13",
      "text": "Within the past twelve months, Prelude Therapeutics, Inc. has been a client of Jefferies Financial Group Inc., its affiliates or subsidiaries and investment banking services are being or have been provided.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "9677f438f35b6d0c",
      "text": "Jefferies Financial Group Inc., its affiliates or subsidiaries beneficially owned \\(1\\%\\) or more of the common equity of Prelude Therapeutics, Inc. as of last month's end (or the prior month's end if this report is dated later than 10 days after the most recent month end).",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "45a14b6dcc805314",
      "text": "Jefferies Financial Group Inc., its affiliates or subsidiaries expect to receive or intend to seek compensation for investment banking services from Protagonist Therapeutics, Inc. within the next three months.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "729097252f8cbfe4",
      "text": "Within the past 12 months, Jefferies Financial Group Inc., its affiliates or subsidiaries has received compensation from investment banking services from Protagonist Therapeutics, Inc.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "49959eb68360dc6c",
      "text": "Jefferies Financial Group Inc., its affiliates or subsidiaries is acting as a manager or co- manager in the underwriting or placement of securities for Protagonist Therapeutics, Inc. or one of its affiliates.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "1b3fa2c804287026",
      "text": "Jefferies Financial Group Inc., its affiliates or subsidiaries has acted as a manager or co- manager in the underwriting or placement of securities for Protagonist Therapeutics, Inc. or one of its affiliates within the past twelve months.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "6bb480b7e1aae1a3",
      "text": "Within the past twelve months, Protagonist Therapeutics, Inc. has been a client of Jefferies Financial Group Inc., its affiliates or subsidiaries and investment banking services are being or have been provided.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "6021fb6b994a189f",
      "text": "Jefferies Financial Group Inc., its affiliates or subsidiaries is acting as a manager or co- manager in the underwriting or placement of securities for TG Therapeutics, Inc. or one of its affiliates.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "251cb5e7c0cc1d52",
      "text": "Jefferies Financial Group Inc., its affiliates or subsidiaries expect to receive or intend to seek compensation for investment banking services from Vaxart, Inc. within the next three months.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "26f082d3301285c5",
      "text": "Within the past 12 months, Jefferies Financial Group Inc., its affiliates or subsidiaries has received compensation from investment banking services from Vaxart, Inc.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "53a32723ed48ac49",
      "text": "Within the past twelve months, Vaxart, Inc. has been a client of Jefferies Financial Group Inc., its affiliates or subsidiaries and investment banking services are being or have been provided.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "97b578c163b84020",
      "text": "Within the past twelve months, Whitehawk Therapeutics has been a client of Jefferies Financial Group Inc., its affiliates or subsidiaries and investment banking services are being or have been provided.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "1a6b950606d44093",
      "text": "Within the past 12 months, Jefferies Financial Group Inc., its affiliates or subsidiaries has received compensation from investment banking services from Whitehawk Therapeutics.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "10b392927a16978e",
      "text": "Jefferies Financial Group Inc., its affiliates or subsidiaries has acted as a manager or co- manager in the underwriting or placement of securities for Whitehawk Therapeutics or one of its affiliates within the past twelve months.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "a013a5b70ed159f0",
      "text": "Jefferies Financial Group Inc., its affiliates or subsidiaries expect to receive or intend to seek compensation for investment banking services from WAVE Life Sciences Ltd. within the next three months.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "83dde77a114cf54d",
      "text": "Within the past 12 months, Jefferies Financial Group Inc., its affiliates or subsidiaries has received compensation from investment banking services from WAVE Life Sciences Ltd.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "2173ad1a3933aefa",
      "text": "Jefferies Financial Group Inc., its affiliates or subsidiaries is acting as a manager or co- manager in the underwriting or placement of securities for WAVE Life Sciences Ltd. or one of its affiliates.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "955d40195a289ecc",
      "text": "Jefferies Financial Group Inc., its affiliates or subsidiaries has acted as a manager or co- manager in the underwriting or placement of securities for WAVE Life Sciences Ltd. or one of its affiliates within the past twelve months.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "bfc83e83ff3c3d64",
      "text": "Within the past twelve months, WAVE Life Sciences Ltd. has been a client of Jefferies Financial Group Inc., its affiliates or subsidiaries and investment banking services are being or have been provided.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "3666b9e73726a606",
      "text": "Within the past 12 months, Jefferies Financial Group Inc., its affiliates or subsidiaries has received compensation from investment banking services from Zenas Biopharma Inc.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "5d77e4dec6ca4177",
      "text": "Jefferies Financial Group Inc., its affiliates or subsidiaries has acted as a manager or co- manager in the underwriting or placement of securities for Zenas Biopharma Inc or one of its affiliates within the past twelve months.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "959d905e3724cfb1",
      "text": "Within the past twelve months, Zenas Biopharma Inc has been a client of Jefferies Financial Group Inc., its affiliates or subsidiaries and investment banking services are being or have been provided.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "f80a4c344a5bcefc",
      "text": "For Important Disclosure information on companies recommended in this report, please visit our website at https://javatar.bluematrix.com/sellsid/Disclosures.action or call 212.284.2300.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "35d0a87acfca0c89",
      "text": "Explanation of Jefferies RatingsBuy - Describes securities that we expect to provide a total return (price appreciation plus yield) of \\(15\\%\\) or more within a 12- month period. Hold - Describes securities that we expect to provide a total return (price appreciation plus yield) of plus \\(15\\%\\) or minus \\(10\\%\\) within a 12- month period. Underperform - Describes securities that we expect to provide a total return (price appreciation plus yield) of minus \\(10\\%\\) or less within a 12- month period. The expected total return (price appreciation plus yield) for Buy rated securities with an average security price consistently below \\(10\\%\\) or more within a 12- month period as these companies are typically more volatile than the overall stock market. For Hold rated securities with an average security price consistently below \\(10\\) , the expected total return (price appreciation plus yield) is plus or minus \\(20\\%\\) within a 12- month period. For Underperform rated securities with an average security price consistently below \\(10\\) , the expected total return (price appreciation plus yield) is minus \\(20\\%\\) or less within a 12- month period. NR - The investment rating and price target have been temporarily suspended. Such suspensions are in compliance with applicable regulations and/or Jefferies policies.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "2f70caee74fc8089",
      "text": "CS - Coverage Suspended. Jefferies has suspended coverage of this company. NC - Not covered. Jefferies does not cover this company.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "b38c8cfe4a9e2b2f",
      "text": "Restricted - Describes issuers where, in conjunction with Jefferies engagement in certain transactions, company policy or applicable securities regulations prohibit certain types of communications, including investment recommendations.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "616bcab22faa4b16",
      "text": "Monitor - Describes securities whose company fundamentals and financials are being monitored, and for which no financial projections or opinions on the investment merits of the company are provided.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "023111066d87e06d",
      "text": "Valuation MethodologyJefferies' methodology for assigning ratings may include the following: market capitalization, maturity, growth/value, volatility and expected total return over the next 12 months. The price targets are based on several methodologies, which may include, but are not restricted to, analyses of market risk, growth rate, revenue stream, discounted cash flow (DCF), EBITDA, EPS, cash flow (CF), free cash flow (FCF), EV/EBITDA, P/E, PE/growth, P/CF, P/FCF, premium (discount)/average group EV/EBITDA, premium (discount)/average group P/E, sum of the parts, net asset value, dividend returns, and return on equity (ROE) over the next 12 months.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "4ea8f91260b308f8",
      "text": "Jefferies Franchise PicksJefferies Franchise Picks include stock selections from among the best stock ideas from our equity analysts over a 12 month period. Stock selection is based on fundamental analysis and may take into account other factors such as analyst conviction, differentiated analysis, a favorable risk/reward ratio and investment themes that Jefferies analysts are recommending. Jefferies Franchise Picks will include only Buy rated stocks and the number can vary depending on analyst recommendations for inclusion. Stocks will be added as new opportunities arise and removed when the reason for inclusion changes, the stock has met its desired return, if it is no longer rated Buy and/or if it triggers a stop loss. Stocks having 120 day volatility in the bottom quartile of S&P stocks will continue to have a 15% stop loss, and the remainder will have a 20% stop. Franchise Picks are not intended to represent a recommended portfolio of stocks and is not sector based, but we may note where we believe a Pick falls within an investment style such as growth or value.",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "fe0422b78f52209d",
      "text": "Other Companies Mentioned in This Report- ATYR PHARMA, INC. (ATYR: \\(3.38, BUY)- Altimmune, Inc. (ALT:\\) 3.83, BUY)- BioAge Labs Inc (BIOA: \\(4.93, HOLD)- Celldex Therapeutics, Inc. (CLDX:\\) 22.08, BUY)- Corvus Pharmaceuticals, Inc. (CRVS: \\(5.74, BUY)- CureVac N.V. (CVAC:\\) 5.37, HOLD)- CytomX Therapeutics, Inc. (CTMX: \\(2.04, BUY)- Disc Medicine Inc (IRON:\\) 59.65, BUY)- IO Biotech (IOBT: \\(1.58, BUY)- Inovio Pharmaceuticals, Inc. (INO:\\) 2.37, HOLD)- Kiniksa Pharmaceuticals Ltd. (KNSA: \\(33.49, BUY)- Krystal Biotech Inc (KRYS:\\) 147.70, BUY)- Kura Oncology, Inc. (KURA: \\(7.90, BUY)- MBX Biosciences, Inc. (MBX:\\) 15.09, BUY)- NURIX THERAPEUTICS, INC. (NRIX: \\(9.34, BUY)- Nektar Therapeutics (NKTR:\\) 29.86, BUY)- Novavax, Inc. (NVAX: \\(7.47, BUY)- Novo Nordisk (NVO:\\) 56.46, UNDERPERFORM)- Nuvalent Inc (NUVL: \\(76.58, BUY)- Prelude Therapeutics, Inc. (PRLD:\\) 1.21, BUY)- Protagonist Therapeutics, Inc. (PTGX: \\(59.05, BUY)- Replimune Group, Inc. (REPL:\\) 5.40, BUY)- Sana Biotechnology Inc (SANA: \\(3.06, BUY)- Structure Therapeutics (GPCR:\\) 19.30, BUY)- TG Therapeutics, Inc. (TGTX: \\(29.33, BUY)- Tourmaline Bio, Inc. (TRML:\\) 23.40, BUY)- United Therapeutics (UTHR: \\(304.76, BUY)- Vaxart, Inc. (VXRT:\\) 0.39, BUY)- Vaxcyte, Inc. (PCVX: \\(30.79, BUY)- Viking Therapeutics, Inc. (VKTX:\\) 27.05, BUY)- WAVE Life Sciences Ltd. (WVE: \\(9.60, BUY)- Whitehawk Therapeutics (WHWK:\\) 1.81, HOLD)- Zenas Biopharma Inc (ZBIO:\\) 16.00, BUY)",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "47b489f6625f4f6c",
      "text": "Distribution of Ratings",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "ee77e6376baa5536",
      "text": "CountPercentCountPercentCountPercentBUY210760.60%37017.56%1185.60%HOLD121234.86%1078.83%221.82%UNDERPERFORM1584.54%31.90%31.90%",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "90d0d639525457ae",
      "text": "Jefferies does busines and seeks to do busines with companies covered in its research reports, and expects to receive or intends to seek compensation for investment banking services among other activities from such companies. As a result, investors should be aware that Jefferies may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "850ba7e3dfb532e1",
      "text": "Jefferies Equity Research refers to research reports produced by analysts employed by one of the following Jefferies Financial Group Inc. (Jefferies) companies: United States: Jefferies LLC which is an SEC registered broker- dealer and a member of FINRA (and distributed by Jefferies Research Services, LLC, an SEC registered Investment Adviser, to clients paying separately for such research).",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "b9d09901a17c72a8",
      "text": "Canada: Jefferies Securities Inc., which is an investment dealer registered in each of the thirteen Canadian jurisdictions and a dealer member of the Canadian Investment Regulatory Organization, including research reports produced jointly by Jefferies Securities Inc. and another Jefferies entity (and distributed by Jefferies Securities Inc.).",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "95181260685c6d45",
      "text": "Where Jefferies Securities Inc. distributes research reports produced by Jefferies LLC, Jefferies International Limited, Jefferies (Japan) Limited, Tokyo Branch or Jefferies India Private Limited, you are advised that each of Jefferies LLC, Jefferies International Limited, Jefferies (Japan) Limited, Tokyo Branch and Jefferies India Private Limited operates as a dealer in your jurisdiction under an exemption from the dealer registration requirements contained in National Instrument 31- 103 Registration Requirements, Exemptions and Ongoing Registrant Obligations and, as such, each of Jefferies LLC, Jefferies International Limited, Jefferies (Japan) Limited, Tokyo Branch and Jefferies India Private Limited is not required to be and is not a registered dealer or adviser in your jurisdiction. You are advised that where Jefferies LLC or Jefferies International Limited prepared this research report, it was not prepared in accordance with Canadian disclosure requirements relating to research reports in Canada.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "adf3e7d5e4862440",
      "text": "United Kingdom: Jefferies International Limited, which is authorized and regulated by the Financial Conduct Authority, registered in England and Wales No. 1978621; registered office: 100 Bishopsgate, London EC2N 4JL; telephone +44 (0)20 7029 8000; facsimile +44 (0)20 7029 8010.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "14e2d9b61a15c376",
      "text": "Japan: Jefferies (Japan) Limited, Tokyo Branch, which is a securities company registered by the Financial Services Agency of Japan and is a member of the Japan Securities Dealers Association; located at Tokyo Midtown Hibiya 30F Hibiya Mitsui Tower, 1- 1- 2 Yurakucho, Chiyoda- ku, Tokyo 100- 0006; telephone +813 5251 6100; facsimile +813 5251 6101.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "bfe5ea0bd9d969c7",
      "text": "Australia: Jefferies (Australia) Pty Limited (ACN 623 059 898), which holds an Australian financial services license (AFSL 504712) and is located at Level 20, 60 Martin Place, Sydney NSW 2000; telephone +61 2 9364 2800.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "43dacde497489e2f",
      "text": "Dubai: Jefferies International Limited, Dubai branch, which is licensed by the Dubai Financial Services Authority (DFSA Reference Number F007325); registered office Unit L31- 06, L31- 07, Level 31, ICD Brookfield Pace, DIFC, PO Box 121208, Dubai, UAE.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "97e107dc40f3dc0f",
      "text": "This report was prepared by personnel who are associated with Jefferies (Jefferies Securities Inc., Jefferies International Limited, Jefferies GmbH, Jefferies Hong Kong Limited, Jefferies Singapore Limited, Jefferies (Japan) Limited, Tokyo Branch, Jefferies India Private Limited), and Jefferies (Australia) Pty Ltd; or by personnel who are associated with both Jefferies LLC and Jefferies Research Services LLC (\"JRS\"). Jefferies LLC is a US registered broker- dealer and is affiliated with JRS, which is a US registered investment adviser. JRS does not create tailored or personalized research and all research provided by JRS is impersonal. If you are paying separately for this research, it is being provided to you by JRS. Otherwise, it is being provided by Jefferies LLC. Jefferies LLC, JRS, and their affiliates are collectively referred to below as \"Jefferies\". Jefferies may seek to do business with companies covered in this research report. As a result, investors should be aware that Jefferies may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only one of many factors in making their investment decisions. Specific conflict of interest and other disclosures that are required by FINRA, the Canadian Investment Regulatory Organization and other rules are set forth in this disclosure section.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "b32dd60076018659",
      "text": "If you are receiving this report from a non- US Jefferies entity, please note the following: Unless prohibited by the provisions of Regulation S of the U.S. Securities Act of 1933, as amended, this material is distributed in the United States by Jefferies LLC, which accepts responsibility for its contents in accordance with the provisions of Rule 15a- 6 under the US Securities Exchange Act of 1934, as amended. Transactions by or on behalf of any US person may only be effected through Jefferies LLC. In the United Kingdom and European Economic Area this report is issued and/or approved for distribution by Jefferies International Limited (\"JIL\") and/or Jefferies GmbH and is intended for use only by persons who have, or have been assessed as having, suitable professional experience and expertise, or by persons to whom it can be otherwise lawfully distributed. Jefferies LLC, JIL, Jefferies GmbH and their affiliates, may make a market or provide liquidity in the financial instruments referred to in this report; and where they do make a market, such activity is disclosed specifically in this report under \"company specific disclosures\".",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "c255df87be4d9c61",
      "text": "For Canadian investors, this material is intended for use only by professional or institutional investors. None of the investments or investment services mentioned or described herein is available to other persons or to anyone in Canada who is not a permitted client as defined by National Instrument 31- 103 Registration Requirements, Exemptions and Ongoing Registrant Obligations, as applicable. This research report is a general discussion of the merits and risks of a security or securities only, and is not in any way meant to be tailored to the needs and circumstances of any recipient. The information contained herein is not, and under no circumstances is to be construed as, an offer to sell securities described herein, or solicitation of an offer to buy securities described herein, in Canada or any province or territory thereof. Any offer or sale of the securities described herein in Canada will be made only under an exemption from the requirements to file a prospectus with the relevant Canadian securities regulators, if applicable, and only by a dealer properly registered under applicable securities laws or, alternatively, pursuant to an exemption from the dealer registration requirement in the relevant province or territory of Canada in which such offer or sale is made. The information contained herein is under no circumstances to be construed as investment advice in any province or territory of Canada and is not tailored to the needs of the recipient. To the extent that the information contained herein references securities of an issuer incorporated, formed or created under the laws of Canada or a province or territory of Canada, any trades in such securities must be conducted through a dealer registered in Canada. No securities commission or similar regulatory authority in Canada has reviewed or in any way passed judgment upon this research report, the information contained herein or the merits of the securities described herein, and any representation to the contrary is an offence.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "b77403d0e069ffc7",
      "text": "By providing this report, neither JRS nor any other Jefferies entity accepts any authority, discretion, or control over the management of the recipient's assets. Any action taken by the recipient of this report, based on the information in the report, is at the recipient's sole judgment and risk. The recipient must perform his or her own independent review of any prospective investment. If the recipient uses the services of Jefferies LLC (or other affiliated broker-dealers), in connection with a purchase or sale of a security that is a subject of these materials, such broker- dealer may act as principal for its own accounts or as agent for another person. Only JRS is registered with the SEC as an investment adviser, and therefore neither Jefferies LLC nor any other Jefferies affiliate has any fiduciary duty in connection with distribution of these reports.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "5501b69edda4ae13",
      "text": "The price and value of the investments referred to herein and the income from them may fluctuate. Past performance is not a guide to future performance, future returns are not guaranteed, and a loss of original capital may occur. Fluctuations in exchange rates could have adverse effects on the value or price of, or income derived from, certain investments.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "8ab116e42d8932c2",
      "text": "This report may contain forward looking statements that may be affected by inaccurate assumptions or by known or unknown risks, uncertainties, and other important factors. As a result, the actual results, events, performance or achievements of the financial product may be materially different from those expressed or implied in such statements.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "f3a53ee45509d862",
      "text": "This report has been prepared independently of any issuer of securities mentioned herein and not as agent of any issuer of securities. No Equity Research personnel have authority whatsoever to make any representations or warranty on behalf of the issuer(s). Any comments or statements made herein are those of the Jefferies entity producing this report and may differ from the views of other Jefferies entities.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "ff79877ffded9ee9",
      "text": "This report may contain information obtained from third parties, including ratings from credit ratings agencies such as Standard & Poor's, and information derived from third-party or proprietary generative artificial intelligence (Gen AI) models. Jefferies does not guarantee the accuracy, completeness, timeliness or availability of this information, and is not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, or for the results obtained from the use of such content. Neither Jefferies nor any third-party content providers, including providers of Gen AI models, give any express or implied warranties, including, but not limited to, any warranties of merchantability or fitness for a particular purpose or use. Neither Jefferies nor any third-party content provider shall be liable for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or profits and opportunity costs) in connection with any use of their content, including ratings. Credit ratings are statements of opinions and are not statements of fact or recommendations to purchase, hold or sell securities. They do not address the suitability of securities or the suitability of securities for investment purposes, and should not be relied on as investment advice. Reproduction and distribution of third party content in any form is prohibited except with the prior written permission of the related third party.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "d6fbc54e0c0d6acd",
      "text": "Jefferies research reports are disseminated and available electronically, and, in some cases, also in printed form. Electronic research is simultaneously made available to all clients. This report or any portion hereof may not be copied, reprinted, sold, or redistributed or disclosed by the recipient or any third party, by content scraping or extraction, automated processing, or any other form or means, without the prior written consent of Jefferies. Any unauthorized use is prohibited. Neither Jefferies nor any of its respective directors, officers or employees, is responsible for guaranteeing the financial success of any investment, or accepts any liability whatsoever for any direct, indirect or consequential damages or losses arising from any use of this report or its contents. Nothing herein shall be construed to waive any liability Jefferies has under applicable U.S. federal or state securities laws.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "236f94f0376a95c4",
      "text": "For Important Disclosure information relating to JRS, please see https://adviserinfo.sec.gov/IAPD/Content/Common/crd_iapd_Brochure.aspx? BRCHR_VRSN_ID=483878 and https://adviserinfo.sec.gov/Firm/292142 or visit our website at https://javatar.bluematrix.com/sellside/Disclosures.action, or www.jefferies.com, or call 1.888.JEFFERIES.",
      "page": 12,
      "section": null
    }
  ],
  "entities": [
    {
      "entity_id": "2a072a9181830190",
      "name": "ADRs of BioAge Labs Inc",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "d6c80af0962fbb09",
      "name": "ARDs of Disc Medicine Inc",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "677d362d760fc045",
      "name": "BioAge Labs",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "ca4356bcae29e6cf",
      "name": "BioAge Labs Inc",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "f59ceba0cdc452f0",
      "name": "Biomea Fusion",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "7860a2554c61a53f",
      "name": "Canadian Investment",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "84a75dae2bccf700",
      "name": "Celldex Therapeutics",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "15d1c2082bd13613",
      "name": "Clonorgan Biotechnology",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "f684008622607aec",
      "name": "Co announced that FDA has notified Co",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "cbc077fa2c87ab1b",
      "name": "Company Program",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "0c759b57d9ad2ce6",
      "name": "Company Specific",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "8bb7d9a681cb9e40",
      "name": "Company Valuation",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "c7df7ca8bcad32ee",
      "name": "Controlled Transient",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "d7113ede0f3a0b82",
      "name": "Corvus Pharmaceuticals",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "4b9be408e155a05b",
      "name": "Coverage Suspended",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "1937483446ed9ba7",
      "name": "CytomX Therapeutics",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "e9cd18ef1469e32c",
      "name": "DFSA Reference",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "6ba4b0a762d135f4",
      "name": "Dealers Association",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "44ecd0f3843af392",
      "name": "Disc Medicine",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "7a9bbcfa15ce41a2",
      "name": "Disc Medicine Inc",
      "type": "company",
      "aliases": []
    }
  ],
  "data": {
    "figures": [
      {
        "type": "other",
        "title": null,
        "page": 3,
        "axes": null,
        "series": [],
        "figure_id": "97ed617fe40244f3",
        "provenance": {
          "page": 3
        }
      },
      {
        "type": "other",
        "title": null,
        "page": 1,
        "axes": null,
        "series": [],
        "figure_id": "aaa04dc4a7992560",
        "provenance": {
          "page": 1
        }
      }
    ],
    "tables": [],
    "numerical_data": [
      {
        "num_id": "1a6e5e7e39194846",
        "value": 0.1,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "MNKD will receive \\(\\) 5\\$ M upfront and is eligible for up to \\(\\) 35\\$ M development milestones + 10% royalties on net sales of any resulting product. Formulation/ development activities will begin ",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "9aa445c430441b2f",
        "value": 0.105,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ht loss (WL) 1EP, as well as all key 2EPs for all 3 doses tested. At the highest dose 36mg, pts got 10.5% WL vs 2.2% pbo and a decreased in HbA1c of 1.8% vs 0.1% pbo. WL was unsurprisingly lower than ",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "e7afd675a5e90208",
        "value": 0.022000000000000002,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "1EP, as well as all key 2EPs for all 3 doses tested. At the highest dose 36mg, pts got 10.5% WL vs 2.2% pbo and a decreased in HbA1c of 1.8% vs 0.1% pbo. WL was unsurprisingly lower than ATTAIN- 1 (no",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "04187560d8dfe303",
        "value": 0.018000000000000002,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "3 doses tested. At the highest dose 36mg, pts got 10.5% WL vs 2.2% pbo and a decreased in HbA1c of 1.8% vs 0.1% pbo. WL was unsurprisingly lower than ATTAIN- 1 (non- T2D obesity). GI AE/ tolerability ",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "37aa5988587eb56b",
        "value": 0.001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "tested. At the highest dose 36mg, pts got 10.5% WL vs 2.2% pbo and a decreased in HbA1c of 1.8% vs 0.1% pbo. WL was unsurprisingly lower than ATTAIN- 1 (non- T2D obesity). GI AE/ tolerability was comp",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "a4eb70997b6fefc5",
        "value": 0.5,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>Ph2 topline data</td></tr></table> Source: Company reports and Jefferies research Significant (>50% stock movement), high (30-50%), medium (10-30%), modest (<10%) <table><tr><td></td><td></td><td></",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "c4999d564d60fbbe",
        "value": -0.5,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/table> Source: Company reports and Jefferies research Significant (>50% stock movement), high (30-50%), medium (10-30%), modest (<10%) <table><tr><td></td><td></td><td></td><td></td><td></td><td></td",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "3e05651b77310b0a",
        "value": -0.3,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "Company reports and Jefferies research Significant (>50% stock movement), high (30-50%), medium (10-30%), modest (<10%) <table><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "dc6bffbe8f9d7f6f",
        "value": 0.1,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "and Jefferies research Significant (>50% stock movement), high (30-50%), medium (10-30%), modest (<10%) <table><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "9a4ce77cb6471da1",
        "value": 0.5,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr></table> Significant (>50% stock movement), high (30-50%), medium (10-30%), modest (<10%)<endofsentence>",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "dab171f809eb6094",
        "value": -0.5,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "></td><td></td><td></td><td></td><td></td></tr></table> Significant (>50% stock movement), high (30-50%), medium (10-30%), modest (<10%)<endofsentence>",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "a362edb4abb79c33",
        "value": -0.3,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d></td><td></td><td></td></tr></table> Significant (>50% stock movement), high (30-50%), medium (10-30%), modest (<10%)<endofsentence>",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "1e4a1047f33bc927",
        "value": 0.1,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td></td></tr></table> Significant (>50% stock movement), high (30-50%), medium (10-30%), modest (<10%)<endofsentence>",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "32f70517465d52ff",
        "value": 0.15,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "loss. Stocks having 120 day volatility in the bottom quartile of S&P stocks will continue to have a 15% stop loss, and the remainder will have a 20% stop. Franchise Picks are not intended to represent",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "c4ee129eaaa26bd1",
        "value": 0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "bottom quartile of S&P stocks will continue to have a 15% stop loss, and the remainder will have a 20% stop. Franchise Picks are not intended to represent a recommended portfolio of stocks and is not ",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "d2d163ae5a0e6300",
        "value": 0.606,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>Count</td><td>Percent</td><td>Count</td><td>Percent</td></tr><tr><td>BUY</td><td>2107</td><td>60.60%</td><td>370</td><td>17.56%</td><td>118</td><td>5.60%</td></tr><tr><td>HOLD</td><td>1212</td><",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "f091eee4a0c3b07f",
        "value": 0.17559999999999998,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>Count</td><td>Percent</td></tr><tr><td>BUY</td><td>2107</td><td>60.60%</td><td>370</td><td>17.56%</td><td>118</td><td>5.60%</td></tr><tr><td>HOLD</td><td>1212</td><td>34.86%</td><td>107</td><",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "24eab1bde0780a1c",
        "value": 0.055999999999999994,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ent</td></tr><tr><td>BUY</td><td>2107</td><td>60.60%</td><td>370</td><td>17.56%</td><td>118</td><td>5.60%</td></tr><tr><td>HOLD</td><td>1212</td><td>34.86%</td><td>107</td><td>8.83%</td><td>22</td><td",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "fbd592ffd45831c8",
        "value": 0.3486,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "60%</td><td>370</td><td>17.56%</td><td>118</td><td>5.60%</td></tr><tr><td>HOLD</td><td>1212</td><td>34.86%</td><td>107</td><td>8.83%</td><td>22</td><td>1.82%</td></tr><tr><td>UNDERPERFORM</td><td>158<",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "8942c2070787a4f4",
        "value": 0.0883,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "56%</td><td>118</td><td>5.60%</td></tr><tr><td>HOLD</td><td>1212</td><td>34.86%</td><td>107</td><td>8.83%</td><td>22</td><td>1.82%</td></tr><tr><td>UNDERPERFORM</td><td>158</td><td>4.54%</td><td>3</td",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "f732e36b2107d934",
        "value": 0.0182,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ".60%</td></tr><tr><td>HOLD</td><td>1212</td><td>34.86%</td><td>107</td><td>8.83%</td><td>22</td><td>1.82%</td></tr><tr><td>UNDERPERFORM</td><td>158</td><td>4.54%</td><td>3</td><td>1.90%</td><td>3</td>",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "447ae796bb812b79",
        "value": 0.0454,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>107</td><td>8.83%</td><td>22</td><td>1.82%</td></tr><tr><td>UNDERPERFORM</td><td>158</td><td>4.54%</td><td>3</td><td>1.90%</td><td>3</td><td>1.90%</td></tr></table><endofsentence>",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "e5b8e2044f017b03",
        "value": 0.019,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>22</td><td>1.82%</td></tr><tr><td>UNDERPERFORM</td><td>158</td><td>4.54%</td><td>3</td><td>1.90%</td><td>3</td><td>1.90%</td></tr></table><endofsentence>",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "ea753e1b8089d8e2",
        "value": 0.019,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "%</td></tr><tr><td>UNDERPERFORM</td><td>158</td><td>4.54%</td><td>3</td><td>1.90%</td><td>3</td><td>1.90%</td></tr></table><endofsentence>",
        "provenance": {
          "page": 9
        }
      }
    ],
    "claims": [],
    "relations": [],
    "extraction_summary": {
      "figures_count": 2,
      "tables_count": 0,
      "numerical_data_count": 24,
      "passages_count": 132,
      "entities_count": 20
    }
  }
}